BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 24, 2013
View Archived Issues
ASP-1017FM has potentially beneficial effects on migraine
Read More
Hanmi Science discloses new protein kinase inhibitors for cancer
Read More
Pulmatrix commences phase Ib COPD study
Read More
Novel agents for metabolic diseases disclosed by Cadila Healthcare
Read More
Genmab submits IND to conduct phase I study of HuMax-TF-ADC
Read More
Gilead Sciences presents novel agents for HIV infection
Read More
Researchers at Rutgers disclose new antibacterial RNA polymerase inhibitors
Read More
Daiichi Sankyo and Ube Industries synthesize new CETP inhibitors
Read More
Experiments profile preclinical activity of Alzheimer's disease candidate AZD-3293
Read More
Novel drug and drug target for the treatment of addictive disorders characterized
Read More
Noven Pharmaceuticals reports topline results from phase II d-ATS
Read More
Results of a phase I evaluation of antigen-specific tolerance for multiple sclerosis
Read More
Ligand signs license agreement with Azure Biotech for lasofoxifene
Read More
New biomaterial coatings to improve bone-bioimplant interface stability
Read More
Cellular Biomedicine begins phase I trial of adipose-derived mesenchymal progenitor cells
Read More
Johnson & Johnson reviews second quarter 2013
Read More
Aquinox begins dosing in phase II trial of AQX-1125 in BPS/IC
Read More
Protalex continues enrollment in phase Ib trial of PRTX-100 following third interim review
Read More
Mast Therapeutics' QT study of MST-188 meets primary endpoint
Read More
Charleston Laboratories completes pre-IND meeting regarding migraine treatment
Read More
Phase III trial comparing obinutuzumab to Rituxan in CLL meets primary endpoint
Read More
Arrowhead commences phase I trial of RNAi therapeutic
Read More
Quest PharmaTech and AD Biotech form joint venture
Read More
Trovagene's reports validation of assay for detecting BRAF mutation in urine
Read More
Roche launches new drug monitoring tests for immunosuppressive therapies
Read More